Omura Tomohiro, Nomura Luna, Watanabe Ran, Nishiguchi Hiroki, Yamamoto Kazuhiro, Imai Satoshi, Nakagawa Shunsaku, Itohara Kotaro, Yonezawa Atsushi, Nakagawa Takayuki, Kunimasa Junichi, Yano Ikuko, Matsubara Kazuo
Department of Pharmacy, Kobe University Hospital, Kobe, Japan.
Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
Front Mol Neurosci. 2021 Dec 9;14:748026. doi: 10.3389/fnmol.2021.748026. eCollection 2021.
Endoplasmic reticulum (ER) stress has been reported as a cause of Parkinson's disease (PD). We have previously reported that the ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) and its stabilizing factor suppressor/enhancer lin-12-like (SEL1L) participate in the ER stress. In addition, we recently demonstrated that neuronal cell death is enhanced in the cellular PD model when SEL1L expression is suppressed compared with cell death when HRD1 expression is suppressed. This finding suggests that SEL1L is a critical key molecule in the strategy for PD therapy. Thus, investigation into whether microRNAs (miRNAs) regulate SEL1L expression in neurons should be interesting because relationships between miRNAs and the development of neurological diseases such as PD have been reported in recent years. In this study, using miRNA databases and previous reports, we searched for miRNAs that could regulate SEL1L expression and examined the effects of this regulation on cell death in PD models created by 6-hydroxydopamine (6-OHDA). Five miRNAs were identified as candidate miRNAs that could modulate SEL1L expression. Next, SH-SY5Y cells were exposed to 6-OHDA, following which miR-101 expression was found to be inversely correlated with SEL1L expression. Therefore, we selected miR-101 as a candidate miRNA for SEL1L modulation. We confirmed that miR-101 directly targets the SEL1L 3' untranslated region, and an miR-101 mimic suppressed the 6-OHDA-induced increase in SEL1L expression and enhanced cell death. Furthermore, an miR-101 inhibitor suppressed this response. These results suggest that miR-101 regulates SEL1L expression and may serve as a new target for PD therapy.
内质网(ER)应激已被报道为帕金森病(PD)的一个病因。我们之前报道过泛素连接酶HMG-CoA还原酶降解蛋白1(HRD1)及其稳定因子抑制子/增强子lin-12样蛋白(SEL1L)参与内质网应激。此外,我们最近证明,与抑制HRD1表达时的细胞死亡相比,在细胞性PD模型中,当SEL1L表达被抑制时神经元细胞死亡会增强。这一发现表明SEL1L是PD治疗策略中的一个关键分子。因此,研究微小RNA(miRNA)是否调节神经元中SEL1L的表达会很有意思,因为近年来已报道了miRNA与诸如PD等神经疾病发展之间的关系。在本研究中,我们利用miRNA数据库和先前的报道,搜索了可能调节SEL1L表达的miRNA,并检测了这种调节对由6-羟基多巴胺(6-OHDA)创建的PD模型中细胞死亡的影响。鉴定出了5种miRNA作为可能调节SEL1L表达的候选miRNA。接下来,将SH-SY5Y细胞暴露于6-OHDA,随后发现miR-101的表达与SEL1L的表达呈负相关。因此,我们选择miR-101作为调节SEL1L的候选miRNA。我们证实miR-101直接靶向SEL1L的3'非翻译区,并且miR-101模拟物抑制了6-OHDA诱导的SEL1L表达增加并增强了细胞死亡。此外,miR-101抑制剂抑制了这种反应。这些结果表明miR-101调节SEL1L表达,并且可能成为PD治疗的一个新靶点。